Evidence map›Paper›PMID 25275557›Full record

ArticlePloS one2014

Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.

Mohamed Abdel-Mohsen, Xutao Deng, Ali Danesh, Teri Liegler, Evan S Jacobs, Andri Rauch, Bruno Ledergerber, Philip J Norris, Huldrych F Günthard, Joseph K Wong and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02563509 (Reconstitution of HIV-specific Immunity Against HIV), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02563509 phase1completednot on this mapstarted 2016, after this paper: background citation

Reconstitution of HIV-specific Immunity Against HIV

TypeinterventionalSponsorGuangzhou 8th People's HospitalRan2016 to 2017Enrolled30ConditionsHIVArmsHIV-specific CD8 cells
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Mohamed Abdel-MohsenDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America; Blood Systems Research Institute, San Francisco, California, United States of America.
Xutao DengBlood Systems Research Institute, San Francisco, California, United States of America.
Ali DaneshBlood Systems Research Institute, San Francisco, California, United States of America.
Teri LieglerDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America.
Evan S JacobsBlood Systems Research Institute, San Francisco, California, United States of America.
Andri RauchDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland.
Bruno LedergerberDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Philip J NorrisDepartment of Medicine, University of California San Francisco, San Francisco, California, United States of America; Blood Systems Research Institute, San Francisco, California, United States of America; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America.
Huldrych F GünthardDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Joseph K WongDepartment of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, United States of America.
Satish K PillaiBlood Systems Research Institute, San Francisco, California, United States of America; Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, United States of America.
Blood Systems Research Institute · USUniversity of California, San Francisco · USSan Francisco VA Medical Center · USUniversity Hospital of Bern · CHUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Antiviral Role of APOBEC3 in HIV/HCV Coinfected PatientsK01DA024654 · NIDA · VITALANT · PI PILLAI, SATISH KUMAR · 2008 to 2012
$902k
Role of Gut Associated Lymphoid Tissue in HIV PersistenceR56AI091573 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K · 2011 to 2011
$643k
The contribution of Tcell tolerance to latent HIV infectionI01BX001048 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI WONG, JOSEPH K · 2011 to 2014
–
BLRD VA I01 BX001048Intramural VA VA999999NIAID NIH HHS P30 AI027763NIAID NIH HHS R56 AI091573NIDA NIH HHS 1K01DA024654NIDA NIH HHS K01 DA024654
6 · The paper itself

Abstract

backgroundInterferon-α (IFN-α) treatment suppresses HIV-1 viremia and reduces the size of the HIV-1 latent reservoir. Therefore, investigation of the molecular and immunologic effects of IFN-α may provide insights that contribute to the development of novel prophylactic, therapeutic and curative strategies for HIV-1 infection. In this study, we hypothesized that microRNAs (miRNAs) contribute to the IFN-α-mediated suppression of HIV-1. To inform the development of novel miRNA-based antiretroviral strategies, we investigated the effects of exogenous IFN-α treatment on global miRNA expression profile, HIV-1 viremia, and potential regulatory networks between miRNAs and cell-intrinsic anti-HIV-1 host factors in vivo.

methodsGlobal miRNA expression was examined in longitudinal PBMC samples obtained from seven HIV/HCV-coinfected, antiretroviral therapy-naïve individuals before, during, and after pegylated interferon-α/ribavirin therapy (IFN-α/RBV). We implemented novel hybrid computational-empirical approaches to characterize regulatory networks between miRNAs and anti-HIV-1 host restriction factors.

resultsmiR-422a was the only miRNA significantly modulated by IFN-α/RBV in vivo (p<0.0001, paired t test; FDR<0.037). Our interactome mapping revealed extensive regulatory involvement of miR-422a in p53-dependent apoptotic and pyroptotic pathways. Based on sequence homology and inverse expression relationships, 29 unique miRNAs may regulate anti-HIV-1 restriction factor expression in vivo.

conclusionsThe specific reduction of miR-422a is associated with exogenous IFN-α treatment, and likely contributes to the IFN-α suppression of HIV-1 through the enhancement of anti-HIV-1 restriction factor expression and regulation of genes involved in programmed cell death. Moreover, our regulatory network analysis presents additional candidate miRNAs that may be targeted to enhance anti-HIV-1 restriction factor expression in vivo.

Indexed as

Gene Expression ProfilingHepatitis CHIV-1HIV InfectionsHumansInterferon-alphaMicroRNAsRibavirinInterferon-alphaMicroRNAsRibavirin

Identifiers

PMID25275557
PMCPMC4183579
OpenAlexW2012764787

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.